Figure 4. T cells genetically modified with a lentiviral anti-EpCAM CAR vector effectively treat established ovarian tumours in NSG mice.

NSG mice were i.p. injected with 1 × 10⁷ SKOV3-Luc ovarian cancer cells on day 0. The mice were randomized into three groups (n = 6 per group) before beginning CART cell treatment on day 8. Mice with disseminated ovarian tumours were given a single dose of 1 × 10⁷ CAR T cells (i.p.) or PBS. (A) Bioluminescent images prior to treatment (day 8) and following the treatments (day 15, 22, 29, and 36). (B) Tumor burden over time by bioluminescent imaging. Each mouse is represented by one line. The inhibition of tumour growth by the anti-EpCAM CAR-modified T cells maintained for at least 43 days in most of the treated mice. (C) Kaplan-Meier analysis of survival. For comparison purpose, survival results from Figure 7A and 7B are also shown here. The PBS curve represents the composite survival rate of two independent experiments (n = 12 totally). Statistical analysis of survival data was performed using the log-rank test.